Alchemab Appoints Ben Porter Brown Chief Medical Officer

Evidence Company-issued announcement · Discovery September 10, 2026 · Importance 3/5 · Direction Neutral Summary Alchemab Therapeutics appointed Ben Porter-Brown, M.D., as chief medical officer as the company prepares to initiate a Phase I study of ATLX-2847, a prostaglandin dehydrogenase inhibitor for muscle atrophy, by…